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in patients with cocaine-associated chest pain who do not have evidence of ischemia or
cardiovascular complications, but there is no study in literature assessing the cost benefit
and readmission rate of IT vs. NIT in patients with CICP admitted to the hospital.
Methods: Retrospectively data of 83 consecutive patients from 2002-2010 who were
admitted with CICP with positive urine drug screen was analyzed. Cost of admission of
each patient was calculated by including cost of hospital stay, medications, laboratory tests,
EKG, cardiac stress test and left heart catheterization. IT arm included patients who
underwent left heart catheterization (LHC), NIT arm included patients managed
conservatively (with or without stress test). Medical records of these patients were
followed for 2 years to look at the number of readmissions for CICP. A Man-Whitney
U test was calculated to compare cost in the IT vs. NIT. A Chi-square test was done, to
compare the incidence of readmissions between the two groups.
Results: Among patients with CICP, 17 patients underwent IT, 66 patients were
managed conservatively (NIT). Overall, average length of stay was 2.7 days and cost of
hospitalization was $5336.54. Man-Whitney U test revealed that the total hospitalization
cost in the IT group (M-place69.24) was significantly higher (U98.000, p0.001)
than the NIT group (M-place34.98). Median cost in IT group was $8626.06 vs. $3674
in NIT group. 16 patients had at least one readmission in 2 years. Overall, there were 41
re-admissions (Average 0.59 readmissions per person in 2 years). There was no significant
difference in the number of readmission between the IT and NIT groups [Chi-square
(DF1) 1.108, p0.293]
Conclusion: Patient admitted with CICP who were managed conservatively had lower
cost of management and similar number of readmissions compared to subjects who were
managed invasively. Conservative management can be preferred in patients with CICP.
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Background: Historically, women with cardiovascular (CV) disease have more comor-
bidities and a higher risk for major CV events and death than men. Outcomes following
percutaneous coronary intervention with new generation drug-eluting stents suggest this
disparity between sexes is decreasing. Nevertheless, there are clear biological differences
between men and women that impact the risk for CV events. Long-term outcomes
following treatment with the Resolute™ zotarolimus-eluting stent (R-ZES) have not
been reported according to sex.
Methods: Patient-level data was pooled from RESOLUTE All Comers (N1140),
RESOLUTE (N139), RESOLUTE US (N1402), RESOLUTE-International
(N2349) and RESOLUTE-Japan (N100) and stratified by sex. Two-year safety
endpoints were compared between the groups after propensity score adjustment for
differences in baseline characteristics. Endpoints include cardiac death, target-vessel
myocardial infarction (TV-MI), clinically-driven target lesion revascularization (TLR),
target-lesion failure (TLF; composite of cardiac death, TV-MI and TLR) and definite/
probable stent thrombosis (ST) through 2 years. All RESOLUTE trials prescribed at least
six months dual antiplatelet therapy.
Results: There were 3,842 men and 1,288 women evaluated. Men were younger (62.8
vs 66.9 yrs, p.001), less likely to have diabetes (27.2% vs 38.0%, p.001) and more like
to have had a prior MI (28.5% vs 20.3%, p.001). Men had longer lesions (15.9 vs 15.1
mm, p.001) a larger pre-procedure diameter stenosis (75.9% vs 74.3%, p.001). At 2
years there was no significant difference in any endpoint between the sexes. TLF was 9.0%
for men vs 10.2% for women; cardiac death plus TV-MI was 5.0% in men and 6.6% in
women. Rates of late and very late ST were 0.2% and 0.1% for men and 0.2% for women
at both timepoints.
Conclusions: When adjusted for baseline differences in clinical and lesion characteristics,
there was no increase in CV events among women treated with R-ZES compared with
men. At 2 years after R-ZES treatment, event rates were low and similar for both men
and women.
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Background: Patients with iodinated contrast dye allergy usually receive premedication
before diagnostic angiography and percutaneous intervention. Whether the contrast dye
allergy or the premedication affects these patients’ risk for contrast-induced nephropathy
or their long-term outcomes is not known. We studied the association between dye allergy
and long-term outcomes in patients undergoing diagnostic angiography and percutaneous
intervention.
Methods and Results: We studied 2713 predominantly (98%) male patients under-
going peripheral and coronary angiography/cardiac catheterization and percutaneous
coronary and endovascular intervention. The mean age was 68 years. A total of 128 (4.7%)
patients had contrast dye allergy. The dye allergy patients had similar baseline creatinine,
and did not differ in medical therapy from the patients without dye allergy. Information
on creatinine at 3 months was available on 1327 patients. Renal dysfunction occurred in
6 (8.82%) patients with dye allergy and 170 (13.5%) in patients without allergy at 3
months after the procedure (odds ratio [OR] 0.62; 95% confidence interval [CI]
0.26-1.46; P0.24). After a follow-up of 60 months, 1 patient (0.78%) of the dye allergy
group was placed on dialysis versus 42 (1.62 %) patients of the group without dye allergy
(OR 0.48, CI 0.07-3.49; P0.46) and 21 patients (16.41%) died of any cause among the
group with dye allergy versus 600 (23.21%) patients of the no allergy group (OR 0.65, CI
0.40-1.05; P0.06). On multivariate analysis, after adjustment for age, comorbidities and
baseline creatinine, dye allergy was not significantly associated with renal dysfunction at 3
months (OR 1.02, CI 0.52-1.99; P0.94), and with starting of dialysis (OR 0.63, CI
0.28-47.69; P0.63) but was significantly and inversely associated with death (OR 0.50,
CI 0.24-0.82; P0.007).
Conclusion: In this cohort of patients, iodinated contrast dye allergy was not associated
with the development of renal dysfunction at 3 months after diagnostic angiography or
percutaneous intervention or of long-term development of end-stage renal disease
requiring dialysis. The association between dye allergy and reduced mortality needs to be
confirmed in a larger cohort.
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Introduction: Coronary angiography (CAG) is a commonly performed procedure in
cardiology, resulting in patients being exposed to radiation. Patients with high body mass
index (BMI) are at increased risk of coronary artery disease. Catheter laboratory
intensifiers use automatic exposure control (AEC) which adjusts radiation dose aiming to
provide optimal quality images. Factors shown to be responsible for dose variability are
complexity of the procedure, operator experience, their level of training in radiation
protection, type and performance of x-ray equipment. The objective of present study was
to evaluate if radiation dose received by patients correlated with BMI.
Method: Retrospective data for 3678 CAG performed from Sep-07 to Mar-10 from a
single centre, were analysed. Radiation dose was calculated as Dose Area Product (DAP)
in mGym2.
Results: Mean radiation dose during the procedure was 4339  286 mGym2. Mean
BMI, contrast volume used and screening time were 29.22 0.08 kg/m2, 125 10.0 ml
and 5.2  0.1 minutes respectively. BMI was positively correlated with increasing
radiation dose during CAG (graph-1 & 2). Patients with increased BMI did not require
prolonged procedure or increased contrast volume. There was no significant inter-operator
variability. Even Ten degree increase in angulation (oblique, cranial or caudal) increased
radiation dose significantly.
Conclusion: Patients with increased BMI receive a significantly higher radiation dose
during CAG, affecting not only the patient, but every one present in the catheter
laboratory. This has to be recognized by the operator when undertaking procedures in
patients with a high BMI.
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